
2-Butoxyethyl 3-pyridinecarboxylate
Nicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option. Nevertheless, it is predominantly found paired with nonivamide as a combination topical analgesic product where its proposed mechanism of action as a rubefacient is complementary and ultimately synergistic with nonivamide's capsaicin activity. Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia. Despite topical nicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared to the oral non-steroidal anti-inflammatory drugs and opioids that may be more typically prescribed. — DrugBank
- IUPAC name
- 2-butoxyethyl pyridine-3-carboxylate
- Molecular formula
- C12H17NO3
- Molecular weight
- 223.27 g/mol
- Exact mass
- 223.12084340 Da
- XLogP3
- 2.1
- Topological polar surface area
- 48.4 Ų
- Hydrogen-bond donors
- 0
- Hydrogen-bond acceptors
- 4
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
- ChEBI:CHEBI:32322
- ChEMBL:CHEMBL2105161
- EPA DTXSID:DTXSID4057635
- PubMed:28008281
- PubMed:25929250
- PubMed:19588430
- PubMed:13825636
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.